Adverse reactions to new drugs.
作者信息
Venning G R
出版信息
Br Med J (Clin Res Ed). 1983 Mar 26;286(6370):1052-3. doi: 10.1136/bmj.286.6370.1052.
Abstract
摘要
相似文献
1
Adverse reactions to new drugs.新药的不良反应。
Br Med J (Clin Res Ed). 1983 Mar 26;286(6370):1052-3. doi: 10.1136/bmj.286.6370.1052.
2
Postmarketing surveillance of adverse reactions to drugs.药品不良反应的上市后监测。
Br Med J (Clin Res Ed). 1984 Mar 24;288(6421):879-80. doi: 10.1136/bmj.288.6421.879.
3
Postmarketing surveillance of adverse reactions to drugs.药品不良反应的上市后监测。
Br Med J (Clin Res Ed). 1984 Apr 14;288(6424):1155-6. doi: 10.1136/bmj.288.6424.1155.
4
Post-marketing surveillance of new drugs.新药上市后监测
J R Coll Gen Pract. 1987 Aug;37(301):337-8.
5
Monitoring of drugs after marketing.药品上市后监测
J R Coll Gen Pract. 1983 Jul;33(252):438-41.
6
Prescription-event monitoring and yellow cards.
Lancet. 1984 Jun 9;1(8389):1301. doi: 10.1016/s0140-6736(84)92486-3.
7
Techniques of postmarketing surveillance. An overview.上市后监测技术。概述。
Med Toxicol. 1986 Jul-Aug;1(4):237-46. doi: 10.1007/BF03259840.
8
Better reporting of adverse drug reactions.
Ann Intern Med. 1985 Feb;102(2):264-5. doi: 10.7326/0003-4819-102-2-264.
9
Postmarketing surveillance of adverse drug reactions: problems and solutions.药品不良反应的上市后监测：问题与解决方案
CMAJ. 1986 Jul 1;135(1):27-32.
10
Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods.药物不良反应的发现。选定的IV期研究与自发报告方法的比较。
JAMA. 1983;249(16):2226-28. doi: 10.1001/jama.249.16.2226.
引用本文的文献
1
Involving the patient in reporting adverse drug reactions.让患者参与药品不良反应报告。
J R Coll Gen Pract. 1988 Aug;38(313):370-1.
Zotero 插件